The estimated Net Worth of Sean Brynjelsen is at least $6.93 Millón dollars as of 22 September 2022. Mr. Brynjelsen owns over 10,000 units of Eton Pharmaceuticals stock worth over $4,981,600 and over the last 6 years he sold ETON stock worth over $0. In addition, he makes $1,946,410 as President, Chief Executive Officer y Director at Eton Pharmaceuticals.
Sean has made over 6 trades of the Eton Pharmaceuticals stock since 2018, according to the Form 4 filled with the SEC. Most recently he bought 10,000 units of ETON stock worth $21,000 on 22 September 2022.
The largest trade he's ever made was buying 10,000 units of Eton Pharmaceuticals stock on 22 September 2022 worth over $21,000. On average, Sean trades about 3,846 units every 108 days since 2018. As of 22 September 2022 he still owns at least 1,040,000 units of Eton Pharmaceuticals stock.
You can see the complete history of Mr. Brynjelsen stock trades at the bottom of the page.
Sean E. Brynjelsen serves as President, Chief Executive Officer, Director of the Company. He has held multiple senior management positions in the pharmaceutical industry over the last 25 years. Prior to joining Eton, Mr. Brynjelsen served as Corporate Officer and Executive Vice President, Business Development, at Sagent Pharmaceuticals, Inc., where he made a number of successful transactions, and the company ultimately was acquired by Nichi-Iko Pharmaceuticals Co., Ltd. for $736MM. Prior to his tenure at Sagent, he was Senior Vice President, Global Business Development for Akorn and executed numerous product and M&A transactions. The company had a market cap of approximately $3 billion when he left the company in 2016 and revenues had increased from $70MM to over $1.1B during his tenure. Earlier in his career, Mr. Brynjelsen spent a number of years in product development focused on sterile pharmaceuticals at both Baxter and Pfizer (formerly Hospira). Mr. Brynjelsen is also a named inventor on several U.S. patents in the fields of drug delivery and formulation science. Mr. Brynjelsen earned an MBA degree from the University of Notre Dame and holds a Master of Science in Chemistry and a Bachelor of Science in Biochemistry from the University of Illinois.
As the President, Chief Executive Officer y Director of Eton Pharmaceuticals, the total compensation of Sean Brynjelsen at Eton Pharmaceuticals is $1,946,410. There are no executives at Eton Pharmaceuticals getting paid more.
Sean Brynjelsen is 48, he's been the President, Chief Executive Officer y Director of Eton Pharmaceuticals since 2017. There are 7 older and 1 younger executives at Eton Pharmaceuticals. The oldest executive at Eton Pharmaceuticals, Inc. is Charles Casamento, 75, who is the Independent Director.
Sean's mailing address filed with the SEC is C/O ETON PHARMACEUTICALS, INC., 21925 W. FIELD PARKWAY, SUITE 235, DEERPARK, IL, 60010-7208.
Over the last 6 years, insiders at Eton Pharmaceuticals have traded over $20,773,599 worth of Eton Pharmaceuticals stock and bought 488,500 units worth $3,287,585 . The most active insiders traders include Management Inc. Opaleye, Mark L Baum y Health, Inc. Harrow. On average, Eton Pharmaceuticals executives and independent directors trade stock every 61 days with the average trade being worth of $746,905. The most recent stock trade was executed by Sean Brynjelsen on 22 September 2022, trading 10,000 units of ETON stock currently worth $21,000.
Eton Pharmaceuticals, Inc., a specialty pharmaceutical company, focuses on developing and commercializing pharmaceutical products for rare diseases. The company offers Biorphen, a phenylephrine injection for the treatment of clinically important hypotension resulting primarily from vasodilation in the setting of anesthesia; Carglumic Acid for the treatment of acute and chronic hyperammonemia due to N-acetylglutamate Synthase deficiency; and Rezipres, a ready-to-use formulation of a molecule that is indicated for the treatment of clinically important hypotension occurring in the setting of anesthesia. It also offers Alkindi Sprinkle, a replacement therapy for adrenocortical insufficiency in children under 17 years of age; EPRONTIA, a liquid formulation of topiramate; and Alaway Preservative Free, a preservative-free ophthalmic product to treat allergic conjunctivitis. In addition, the company develops Zonisamide Oral Suspension for the treatment of partial on-set seizures; Lamotrigine for Oral Suspension for the treatment of partial on-set seizures; cysteine injection; dehydrated alcohol injection; and Zeneo hydrocortisone autoinjector. Eton Pharmaceuticals, Inc. was incorporated in 2017 and is based in Deer Park, Illinois.
Eton Pharmaceuticals executives and other stock owners filed with the SEC include: